Lumos Diagnostics Holdings Fiscal H1 Revenue Falls Slightly; Shares Up 3%

MT Newswires Live

Yesterday

Lumos Diagnostics Holdings (ASX:LDX) said its revenue for the six months ended Dec. 31, 2025, came in at AU$6.1 million, compared with AU$6.3 million in the prior-year period, according to a Friday Australian bourse filing.

Under its development agreement with Hologic, the company is working on the development of Hologic's fFN diagnostic product for pre-term birth, including adapting the test for use on Lumos' proprietary reader platform. The scope of work was expanded on three occasions, increasing total potential milestone payments to between AU$6.5 million and AU$7 million. The estimated project completion timeline was extended to February 2027.

The reduction in services revenue of AU$1 million during the period was driven by less revenue recognized from the intellectual property agreement with Hologic.

Lumos Diagnostics Holdings' shares rose nearly 3% in recent trading on Friday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2614623005"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614623005\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614623005?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 08:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614623005","market":"fut","top_or_hot":-1,"title":"Lumos Diagnostics Holdings Fiscal H1 Revenue Falls Slightly; Shares Up 3%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/LDXHF\">Lumos Diagnostics</a> Holdings (ASX:LDX) said its revenue for the six months ended Dec. 31, 2025, came in at AU$6.1 million, compared with AU$6.3 million in the prior-year period, according to a Friday Australian bourse filing.</p><p>Under its development agreement with Hologic, the company is working on the development of Hologic's fFN diagnostic product for pre-term birth, including adapting the test for use on Lumos' proprietary reader platform. The scope of work was expanded on three occasions, increasing total potential milestone payments to between AU$6.5 million and AU$7 million. The estimated project completion timeline was extended to February 2027.</p><p>The reduction in services revenue of AU$1 million during the period was driven by less revenue recognized from the intellectual property agreement with Hologic.</p><p><a href=\"https://laohu8.com/S/LDX.AU\">Lumos Diagnostics</a> Holdings' shares rose nearly 3% in recent trading on Friday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lumos Diagnostics Holdings Fiscal H1 Revenue Falls Slightly; Shares Up 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLumos Diagnostics Holdings Fiscal H1 Revenue Falls Slightly; Shares Up 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-27 08:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/LDXHF\">Lumos Diagnostics</a> Holdings (ASX:LDX) said its revenue for the six months ended Dec. 31, 2025, came in at AU$6.1 million, compared with AU$6.3 million in the prior-year period, according to a Friday Australian bourse filing.</p><p>Under its development agreement with Hologic, the company is working on the development of Hologic's fFN diagnostic product for pre-term birth, including adapting the test for use on Lumos' proprietary reader platform. The scope of work was expanded on three occasions, increasing total potential milestone payments to between AU$6.5 million and AU$7 million. The estimated project completion timeline was extended to February 2027.</p><p>The reduction in services revenue of AU$1 million during the period was driven by less revenue recognized from the intellectual property agreement with Hologic.</p><p><a href=\"https://laohu8.com/S/LDX.AU\">Lumos Diagnostics</a> Holdings' shares rose nearly 3% in recent trading on Friday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LDX.AU","symbol_name":"LUMOS DIAGNOSTICS HOLDINGS L","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2614623005","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614623005","pubTimestamp":1772153294,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Lumos Diagnostics Holdings  said its revenue for the six months ended Dec. 31, 2025, came in at AU$6.1 million, compared with AU$6.3 million in the prior-year period, according to a Friday Australian bourse filing.Under its development agreement with Hologic, the company is working on the development of Hologic's fFN diagnostic product for pre-term birth, including adapting the test for use on Lumos' proprietary reader platform. The scope of work was expanded on three occasions, increasing total potential milestone payments to between AU$6.5 million and AU$7 million. The estimated project completion timeline was extended to February 2027.The reduction in services revenue of AU$1 million during the period was driven by less revenue recognized from the intellectual property agreement with Hologic.Lumos Diagnostics Holdings' shares rose nearly 3% in recent trading on Friday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LDX.AU":"LUMOS DIAGNOSTICS HOLDINGS L","BK7126":"医疗保健用品"},"translate_title":"Lumos Diagnostics Holdings上半年收入略有下降；股价上涨3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LDX.AU":1},"content_text":"Lumos Diagnostics Holdings (ASX:LDX) said its revenue for the six months ended Dec. 31, 2025, came in at AU$6.1 million, compared with AU$6.3 million in the prior-year period, according to a Friday Australian bourse filing.Under its development agreement with Hologic, the company is working on the development of Hologic's fFN diagnostic product for pre-term birth, including adapting the test for use on Lumos' proprietary reader platform. The scope of work was expanded on three occasions, increasing total potential milestone payments to between AU$6.5 million and AU$7 million. The estimated project completion timeline was extended to February 2027.The reduction in services revenue of AU$1 million during the period was driven by less revenue recognized from the intellectual property agreement with Hologic.Lumos Diagnostics Holdings' shares rose nearly 3% in recent trading on Friday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}